Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026.

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026. This is described as the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate.

The company will host a webcast at 8:00 a.m. ET on April 27, 2026 to discuss the topline results; a replay will be available for approximately 90 days.

Positive

• World's first Phase 3 readout for an in vivo CRISPR candidate
• Topline data release scheduled April 27, 2026 with an 8:00 a.m. ET webcast

Negative

• None.

Argus Apr 27 session

-4.33% close to close Open Argus

Details

News Market Reaction – NTLA

On Apr 27, the first trading day after this news, NTLA closed 4.33% below the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Key Figures

Phase 3 readout date: April 27, 2026 Phase 1/2 HAE cohort size: 32 patients (n=32) HAE attack reduction: 96% reduction +5 more

Phase 3 readout date

April 27, 2026

Global Phase 3 HAELO topline for lonvo-z in HAE

Phase 1/2 HAE cohort size

32 patients (n=32)

Pooled lonvo-z Phase 1/2 HAE cohort at 50 mg

HAE attack reduction

96% reduction

Mean reduction in HAE attacks vs baseline in pooled cohort

Attack-free & LTP-free rate

31/32 patients (97%)

Lonvo-z HAE patients at data cutoff in pooled analysis

Plasma kallikrein reduction

89% at month 24

Lonvo-z Phase 1/2 pooled HAE data at 24 months

MAGNITUDE Phase 3 size

~1,200 patients

Planned enrollment for ATTR-CM MAGNITUDE trial (2:1 randomization)

ATTR-CM TTR reduction

87% mean reduction

Nex-z single-dose TTR reduction at 36 months in ATTR-CM

ATM offering size

$400,000,000

Prospectus supplement for at-the-market common stock program

Previous Clinical trial Reports

5 past events · Latest: Mar 03

Same Type 5 events

1. Mar 03

   Lonvo-z HAE data

   24h Move

   -11.9%

   Presented longer-term pooled Phase 1/2 lonvo-z HAE data with strong attack reduction.

2. Mar 02

   MAGNITUDE hold lifted

   24h Move

   +12.1%

   FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial, allowing enrollment to resume.

3. Jan 27

   MAGNITUDE-2 hold lift

   24h Move

   +6.3%

   FDA lifted clinical hold on MAGNITUDE-2 Phase 3 ATTRv-PN trial with enhanced liver monitoring.

4. Nov 10

   Nex-z Phase 1 data

   24h Move

   +2.2%

   Reported longer-term Phase 1 ATTR-CM data showing durable TTR reduction and clinical stability.

5. Nov 08

   Lonvo-z Phase 1/2

   24h Move

   +2.2%

   Presented pooled Phase 1/2 lonvo-z HAE data with high attack-free and LTP-free rates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, in vivo, crispr, gene editing, +2 more

6 terms

phase 3 medical

"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

in vivo medical

"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

crispr medical

"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

gene editing medical

"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"

Gene editing is a set of laboratory techniques that change the DNA inside living cells to add, remove, or alter specific genes, like using precise 'cut-and-paste' tools to edit an instruction manual for a living organism. It matters to investors because successful edits can produce new therapies, improve agricultural products, or create commercial advantages; progress, safety, regulatory approvals, and patent control all affect a company’s value and risk profile.

topline clinical data medical

"announced the company will report topline clinical data from its global Phase 3 HAELO"

Topline clinical data are the initial, high-level results released after a medical study that summarize whether the trial met its main goals and flag any major safety issues. Investors treat them like a headline summary of a longer report: they quickly indicate whether a drug or treatment is likely to move forward with regulators and reach the market, but they don’t include the full details that can change the longer-term story.

hereditary angioedema medical

"clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE)"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate
• Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026

CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website at intelliatx.com. A replay of the webcast will be available for approximately 90 days.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Intellia (NTLA) report topline HAELO Phase 3 data for lonvoguran ziclumeran?

Intellia will report topline Phase 3 HAELO data on April 27, 2026. According to the company, a webcast to discuss the data will begin at 8:00 a.m. ET and a replay will be available for roughly 90 days.

What is significant about the HAELO Phase 3 readout for NTLA's lonvo-z?

The HAELO readout is described as the world's first Phase 3 for an in vivo CRISPR gene editing candidate. According to the company, this marks a milestone in clinical development for in vivo CRISPR therapeutics.

How can investors listen to Intellia's April 27, 2026 webcast about NTLA trial results?

Investors can join the webcast via the Events page in the Investors & Media section on Intellia's website. According to the company, the live event starts at 8:00 a.m. ET and a replay will be posted for about 90 days.

What drug is being evaluated in Intellia's Phase 3 HAELO trial (NTLA)?

The HAELO trial is evaluating lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. According to the company, topline clinical data from the global Phase 3 trial will be reported on April 27, 2026.

Will a replay be available after Intellia's April 27 NTLA webcast and for how long?

Yes, a replay will be available for approximately 90 days following the webcast. According to the company, the replay will be accessible via the Events page in the Investors & Media section of its website.